Novel protocol for multiple-dose oral administration of the L-type Ca²⁺ channel blocker isradipine in mice: A dose-finding pharmacokinetic study

References

• Zamponi GW, Striessnig J, Koschak A, et al. The physiology, pathology, and pharmacology of voltage-gated calcium channels and their future therapeutic potential. Pharmacol Rev. 2015 Oct;67(4):821–10.
   PubMed Web of Science ®Google Scholar
• Alexander SP, Striessnig J, Kelly E, et al. The concise guide to pharmacology 2017/18: voltage-gated ion channels. Br J Pharmacol. 2017 Dec;174 Suppl 1(Suppl Suppl 1):S160–S194.
   PubMedGoogle Scholar
• Liao P, Yu D, Li G, et al. A smooth muscle Cav1.2 calcium channel splice variant underlies hyperpolarized window current and enhanced state-dependent inhibition by nifedipine. J Biol Chem. 2007 Nov 30;282(48):35133–35142. doi: 10.1074/jbc.M705478200
   PubMed Web of Science ®Google Scholar
• Harrison PJ, Tunbridge EM, Dolphin AC, et al. Voltage-gated calcium channel blockers for psychiatric disorders: genomic reappraisal. Br J Psychiatry. 2020 May;216(5):250–253.
   PubMed Web of Science ®Google Scholar
• Filippini L, Ortner NJ, Kaserer T, et al. Ca(v) 1.3-selective inhibitors of voltage-gated L-type Ca(2+) channels: fact or (still) fiction? Br J Pharmacol. 2023 May;180(10):1289–1303.
   PubMed Web of Science ®Google Scholar
• Kabir ZD, Martinez-Rivera A, Rajadhyaksha AM. From gene to behavior: L-type calcium channel mechanisms underlying neuropsychiatric symptoms. Neurotherapeutics. 2017 Jul;14(3):588–613. doi: 10.1007/s13311-017-0532-0
   PubMed Web of Science ®Google Scholar
• Uchida S, Yamada S, Nagai K, et al. Brain pharmacokinetics and in vivo receptor binding of 1,4-dihydropyridine calcium channel antagonists. Life Sci. 1997;61(21):2083–2090. doi: 10.1016/S0024-3205(97)00881-3
   PubMed Web of Science ®Google Scholar
• Shin J, Kovacheva L, Thomas D, et al. Ca(v)1.3 calcium channels are full-range linear amplifiers of firing frequencies in lateral DA SN neurons. Sci Adv. 2022 Jun 10;8(23):eabm4560. doi: 10.1126/sciadv.abm4560
   PubMed Web of Science ®Google Scholar
• Siddiqi FH, Menzies FM, Lopez A, et al. Felodipine induces autophagy in mouse brains with pharmacokinetics amenable to repurposing. Nat Commun. 2019 Apr 18;10(1):1817. doi: 10.1038/s41467-019-09494-2
   PubMedGoogle Scholar
• Ilijic E, Guzman JN, Surmeier DJ. The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson’s disease. Neurobiol Dis. 2011 Aug;43(2):364–371. doi: 10.1016/j.nbd.2011.04.007
   PubMed Web of Science ®Google Scholar
• Bavley CC, Fetcho RN, Burgdorf CE, et al. Cocaine- and stress-primed reinstatement of drug-associated memories elicit differential behavioral and frontostriatal circuit activity patterns via recruitment of L-type Ca(2+) channels. Mol Psychiatry. 2020 Oct;25(10):2373–2391.
   PubMed Web of Science ®Google Scholar
• Ortner NJ, Bock G, Dougalis A, et al. Lower affinity of isradipine for L-type Ca(2+) channels during substantia nigra dopamine neuron-like activity: implications for neuroprotection in Parkinson’s disease. J Neurosci. 2017 Jul 12;37(28):6761–6777. doi: 10.1523/JNEUROSCI.2946-16.2017
   PubMed Web of Science ®Google Scholar
• Tse FL, Jaffe JM, Hassell AE, et al. Bioavailability of isradipine in young and old rats: effect of mode of administration. J Pharm Pharmacol. 1989 Sep;41(9):657–660.
   PubMed Web of Science ®Google Scholar
• Schafe GE. Rethinking the role of L-type voltage-gated calcium channels in fear memory extinction. Learn Mem. 2008 May;15(5):324–325. doi: 10.1101/lm.996908
   PubMed Web of Science ®Google Scholar
• Waltereit R, Mannhardt S, Nescholta S, et al. Selective and protracted effect of nifedipine on fear memory extinction correlates with induced stress response. Learn Mem. 2008 May;15(5):348–356.
   PubMed Web of Science ®Google Scholar
• Ortner NJ, Sah A, Paradiso E, et al. The human channel gating-modifying A749G CACNA1D (Cav1.3) variant induces a neurodevelopmental syndrome-like phenotype in mice. JCI Insight. 2023 Oct 23;8(20). doi: 10.1172/jci.insight.162100
   PubMed Web of Science ®Google Scholar
• Christensen HR, Antonsen K, Simonsen K, et al. Bioavailability and pharmacokinetics of isradipine after oral and intravenous administration: half-life shorter than expected? Pharmacol Toxicol. 2000 Apr;86(4):178–182.
   PubMedGoogle Scholar
• Park JH, Park YS, Rhim SY, et al. Quantification of isradipine in human plasma using LC-MS/MS for pharmacokinetic and bioequivalence study. J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Jan 1;877(1–2):59–64. doi: 10.1016/j.jchromb.2008.11.021
   PubMed Web of Science ®Google Scholar
• Venuto CS, Yang L, Javidnia M, et al. Isradipine plasma pharmacokinetics and exposure-response in early Parkinson’s disease. Ann Clin Transl Neurol. 2021 Mar;8(3):603–612.
   PubMed Web of Science ®Google Scholar
• Shenfield GM, Boutagy J, Stokes GS, et al. The pharmokinetics of isradipine in hypertensive subjects. Eur J Clin Pharmacol. 1990;38(2):209–211. doi: 10.1007/BF00265988
   PubMed Web of Science ®Google Scholar
• Carrara V, Porchet H, Dayer P. Influence of input rates on (±)-isradipine haemodynamics and concentration-effect relationship in healthy volunteers. Eur J Clin Pharmacol. 1994;46(1):29–33. doi: 10.1007/BF00195912
   PubMed Web of Science ®Google Scholar
• Wang Y, Jin Z, Wang Z, et al. Pharmacokinetic properties of isradipine after single-dose and multiple-dose oral administration in Chinese volunteers: a randomized, open-label, parallel-group phase I study. Biomed Chromatogr. 2013 Dec;27(12):1664–1670.
   PubMed Web of Science ®Google Scholar
• Johnson BA, Javors MA, Lam YW, et al. Kinetic and cardiovascular comparison of immediate-release isradipine and sustained-release isradipine among non-treatment-seeking, cocaine-dependent individuals. Prog Neuropsy-chopharmacol Biol Psychiatry. 2005 Jan;29(1):15–20.
   PubMed Web of Science ®Google Scholar
• Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016 Mar;7(2):27–31. doi: 10.4103/0976-0105.177703
   PubMedGoogle Scholar
• Santiapillai J, Tadtayev S, Miles A, et al. Dihydropyridine calcium channel blockers and obstructive sleep apnea: two underrecognized causes of nocturia? Neurourol Urodyn. 2020 Jun;39(5):1612–1614.
   PubMed Web of Science ®Google Scholar
• Striessnig J, Moosburger K, Goll A, et al. Stereoselective photoaffinity labelling of the purified 1,4-dihydropyridine receptor of the voltage-dependent calcium channel. Eur J Biochem. 1986 Dec 15;161(3):603–609. doi: 10.1111/j.1432-1033.1986.tb10484.x
   PubMedGoogle Scholar
• Zernig G, Glossmann H. A novel 1,4-dihydropyridine-binding site on mitochondrial-membranes from guinea-pig heart, liver and kidney. Biochem J. 1988 Jul 1;253(1):49–58. doi: 10.1042/bj2530049
   PubMed Web of Science ®Google Scholar
• Sinnegger-Brauns MJ, Huber IG, Koschak A, et al. Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms. Mol Pharmacol. 2009 Feb;75(2):407–414.
   PubMed Web of Science ®Google Scholar